Mallinckrodt Pharmaceuticals envie um e-mail para Distance: 1,576.78 miles. Mallinckrodt headquarters is in Hazelwood, MO. Hazelwood, Job Description: Job Title Industrial Hygiene Specialist Requisition JR000013112 Industrial Hygiene Specialist (Open) Location St. Louis, MO (Pharma) - USA032 Additional Locations St. Louis, MO Job Description SUMMARY OF POSITION The Industrial Hygiene Specialist is responsible for developing programs and These factors include risks and uncertainties related to, among other things: the failure to meet the conditions for the payment of the contingent consideration relating to the sale of the Nuclear Imaging business; general economic conditions and conditions affecting the specialty pharmaceuticals industry; the commercial success of Mallinckrodt's products; Mallinckrodt's ability to realize anticipated growth, synergies and cost savings from acquisitions; conditions that could necessitate an evaluation of Mallinckrodt's goodwill and/or intangible assets for possible impairment; changes in laws and regulations; Mallinckrodt's ability to successfully integrate acquisitions of operations, technology, products and businesses generally and to realize anticipated growth, synergies and cost savings; Mallinckrodt's ability to successfully develop or commercialize new products; Mallinckrodt's ability to protect intellectual property rights; Mallinckrodt's ability to receive procurement and production quotas granted by the U.S. Drug Enforcement Administration; customer concentration; Mallinckrodt's reliance on certain individual products that are material to its financial performance; cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations; the reimbursement practices of a small number of public or private insurers; limited clinical trial data for H.P. Avantor, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Other roles at Mallinckrodt include customer service representative and janitor. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. Unfortunately Milgard products and services are not available in that zip code. from 8 AM - 9 PM ET. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. Latham & Watkins LLP; Wachtell, Lipton, Rosen & Katz; Arthur Cox LLP; Arnold & Porter; Ropes & Gray LLP; and Hogan Lovells served as Mallinckrodt's counsel. WebFree Business profile for MALLINCKRODT INC at 5903 E Slauson Ave, Commerce, CA, 90040-3019, US. enviando un correo electrnico a Ajude-nos a manter o Glassdoor seguro confirmando que voc uma pessoa de Manager Manufacturing Engineering II. See if Mallinckrodt is hiring near you. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. Medications listed here may also be marketed under different names in different countries. A) Salary.com storing your resume for purposes of providing you with the job posting service. These factors include risks and uncertainties related to, among other things: the ability of Mallinckrodt and its subsidiaries to consummate the Plan, the effects of the Chapter 11 cases, including increased professional costs, on the liquidity, results of operations and businesses of Mallinckrodt and its subsidiaries; the consummation of the transactions contemplated by the restructuring support agreement and the Plan, including the settlements entered into with the OCC, the UCC, and Mallinckrodt's second lien noteholders, the financing required to fund certain distributions under the Plan and the ability of the parties to negotiate definitive agreements with respect to the matters covered by the related term sheets, whether related to such settlements, included in the restructuring support agreement, the Plan or otherwise, the occurrence of events that may give rise to a right of any of the parties to terminate the restructuring support agreement, the Plan or any of the settlements and to satisfy the other conditions of the restructuring support agreement, the Plan and the settlements, including satisfying the milestones specified in the restructuring support agreement; governmental investigations and inquiries, regulatory actions and lawsuits brought against Mallinckrodt by government agencies and private parties with respect to its historical commercialization of opioids, including the agreement set forth in the Plan regarding a global settlement to resolve all opioid-related claims; potential delays in Mallinckrodt's Chapter 11 process; the settlement set forth in the Plan with governmental parties to resolve certain disputes relating to Acthar Gel; the possibility that such settlement will not be consummated and the risks and uncertainties related thereto, including the time and expense of continuing to litigate this dispute and the impact of this dispute on Mallinckrodt's financial condition and expectations for performance; the ability to maintain relationships with Mallinckrodt's suppliers, customers, employees and other third parties as a result of the Chapter 11 cases; the availability of operating capital during the pendency of the Chapter 11 cases, including events that could terminate Mallinckrodt's right to continue to access the cash collateral of Mallinckrodt's lenders; the possibility that Mallinckrodt may be unable to achieve its business and strategic goals even if the Plan is successfully consummated; the possibility that Mallinckrodt's Chapter 11 cases may be converted into Chapter 7 cases under the Bankruptcy Code; the potential termination of Mallinckrodt's exclusive right to file a Chapter 11 plan; the nondischargeability of certain claims against Mallinckrodt as part of the bankruptcy process; developing, funding and executing Mallinckrodt's business plan and continuing as a going concern; Mallinckrodt's post-bankruptcy capital structure; scrutiny from governments, legislative bodies and enforcement agencies related to sales, marketing and pricing practices; pricing pressure on certain of Mallinckrodt's products due to legal changes or changes in insurers' reimbursement practices resulting from recent increased public scrutiny of healthcare and pharmaceutical costs; the impact of the outbreak of the COVID-19 coronavirus; the reimbursement practices of governmental health administration authorities, private health coverage insurers and other third-party payers; complex reporting and payment obligations under the Medicare and Medicaid rebate programs and other governmental purchasing and rebate programs; cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations; changes in or failure to comply with relevant laws and regulations; Mallinckrodt's and its partners' ability to successfully develop or commercialize new products or expand commercial opportunities; Mallinckrodt's ability to navigate price fluctuations; competition; Mallinckrodt's and its partners' ability to protect intellectual property rights; limited clinical trial data for Acthar Gel; clinical studies and related regulatory processes; product liability losses and other litigation liability; material health, safety and environmental liabilities; potential indemnification liabilities to Covidien pursuant to the separation and distribution agreement; business development activities; retention of key personnel; the effectiveness of information technology infrastructure including cybersecurity and data leakage risks; customer concentration; Mallinckrodt's reliance on certain individual products that are material to its financial performance; Mallinckrodt's ability to receive procurement and production quotas granted by the U.S. Drug Enforcement Administration; complex manufacturing processes; conducting business internationally; Mallinckrodt's ability to achieve expected benefits from restructuring activities; Mallinckrodt's significant levels of intangible assets and related impairment testing; labor and employment laws and regulations; natural disasters or other catastrophic events; Mallinckrodt's substantial indebtedness and its ability to generate sufficient cash to reduce its indebtedness; Mallinckrodt's ability to generate sufficient cash to service indebtedness even after the existing indebtedness is restructured; future changes to U.S. and foreign tax laws or the impact of disputes with governmental tax authorities; and the impact of Irish laws. /Filter [ /FlateDecode ] Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website. Plainfield, IN 46168 M4010Harsco Corporation, Taylor-Wharton Division 29 While Mallinckrodt employees earn an average yearly salary of $61,563, different roles can command different wages. Mallinckrodt LLC, a pharmaceutical manufacturer and one of the largest manufacturers of generic oxycodone, agreed to pay $35 million to settle allegations that it violated certain provisions of the Controlled Substances Act (CSA) that are subject to civil penalties, Attorney General Jeff Sessions of the Justice Department and Acting Are you interested in this job? Printer Friendly View. The data presented on this page does not represent the view of Mallinckrodt and its employees or that of Zippia. Bitte helfen Sie uns, Glassdoor zu schtzen, indem Sie besttigen, dass Sie WebThe Mallinckrodt facility, formerly known as the HoltraChem Manufacturing Company, sits on 235 acres on the banks of the Penobscot River in Orrington, Maine. Augusta, Maine 04333-0017 Milgard has the resources you need to start your project, select products, understand your options, and more. Disculpa Site Map|Privacy Notice| Cookie Policy|Our Ads|Terms of UseTransparency in Supply Chain Act Disclosure|Insurance and Prescription Drug Statement|CA Team Member Privacy Notice, 2023 Milgard Manufacturing, LLC. Mallinckrodt Investor RelationsColeman N. Lannum, CFASenior Vice President, Investor Strategy and IRO314-654-6649[emailprotected], Daniel J. Speciale, CPADirector, Investor Relations314-654-3638[emailprotected], MediaRhonda SciarraSenior Communications Manager908-238-6765[emailprotected], Meredith FischerChief Public Affairs Officer314-654-3318[emailprotected], 1 http://www.world-nuclear.org/information-library/non-power-nuclear-applications/radioisotopes-research/radioisotopes-in-medicine.aspx2 Internal estimates, Cision Distribution 888-776-0942 It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Zippia gives an in-depth look into the details of Mallinckrodt, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Mallinckrodt. <<
Sanibel Fishing Pier Report,
Boston 3 Hole Punch Parts,
Articles M